Background. Randomized controlled trials on the post-admission use of statins in sepsis patients have not shown a survival benefit. Whether preadmission use of statins would confer any beneficial effects in sepsis patients has not been well studied. Methods. We conducted a population-based cohort study on a national health insurance claims database between 1999 and 2011. Sepsis patients were identified by ICD-9 codes compatible with the third International consensus definitions for sepsis. Use of statin was defined as the cumulative use of any statin for more than 30 days before the indexed sepsis admission. We determined the association between statin use and sepsis outcome by multivariate-adjusted Cox proportional hazard models and propensity score matched analysis. To minimize baseline imbalance between statin users and non-statin users, we matched/adjusted for social economic status, comorbidities, proxies for healthy lifestyle, health care facility utilization, and use of medications. Results. We identified 52 737 sepsis patients, of which 3599 received statin treatment. Statins use was associated with a reduced 30-day mortality after multivariable adjustment (HR 0.86, 95% CI, 0.78-0.94) and propensity score matching (HR, 0.88; 95% CI, 0.78-0.99). On subgroup analysis, the beneficial effects of statins were not significant in patients receiving ventilator support or requiring ICU admission. Conclusions. In this national cohort study, preadmission statin therapy before sepsis development was associated with a 12% reduction in mortality when compared with patients who never received a statin. There were no consistent beneficial effects of statins in all patient subgroups.
The incidence of sepsis has increased over the last few decades. Globally, an estimated 20 to 30 million patients develop sepsis annually, leading to more than 8.7 million deaths each yr. 1 Although much progress has been made in the diagnosis and management of sepsis, its outcome remains grave, with a casefatality rate around 24 to 30%. [1] [2] [3] [4] [5] Statins, as 3-hydroxy-3-methylglutaryl-coenzyme-A inhibitors, are a class of commonly used cholesterol modulating medications for primary and secondary prevention of cardiovascular diseases. 6 In animal studies, statins have shown pleiotropic effects on sepsis' outcome, modulating the balance between pro-inflammatory and anti-inflammatory cytokines, stimulating the activity of both leukocytes and monocytes, reducing the oxidative stress, and counteracting the harmful effects of sepsis on the coagulation system. [7] [8] [9] [10] [11] While in animal studies statin treatment was associated with a favorable outcome in sepsis, human studies have been contradictory with varying results depending on the study design. 12 13 In fact, observational studies generally demonstrated a favorable effect for statin treatment, while randomized controlled trials (RCTs) tended to have negative results. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] The trial conducted by Kruger and colleagues might provide some insight on the conflicting results between observation studies and RCTs 16 . They discovered that the habitual use of statins (i.e. chronic use of any statins for at least two weeks before the sepsis onset) rather than de novo statin therapy (treatment with statins on admission to the emergency care) was associated with a lower baseline IL-6 concentration and improved survival. 16 Timing of statin therapy could be the key to solve this Gordian knot: most of the trials that previously failed to show a beneficial effect of statins were in fact conducted on de novo statin users, while most observational studies were conducted on habitual statin users. Kruger and colleagues' evidence is also supported by the pharmacokinetic properties of statins, which the anti-inflammatory abilities require appropriate treatment duration before taking effect (at least 14 days). 8 11 27 Despite the implication from Kruger's trial, 16 the generalizability and validity of the outcome might be limited by its relatively small sample size. Only 37 prior statin users were compared with the placebo group. We believed the hypothesis that habitual use of statins might exert beneficial effects in sepsis patients deserved a validation in a sufficiently powered database. Therefore, we sought to evaluate the effect of the chronic prior use of statins in a large population-based database.
Methods

Data source
We conducted a cohort study using the National Health Insurance Research Database (NHIRD) of Taiwan, with approval from the institutional review board of the National Taiwan University Hospital. The NHIRD is a one-million longitudinal cohort randomly sampled from the entire Taiwanese population by a stratified probability-sampling scheme based on the patient characteristic distribution in 2000. The database is a longitudinal cohort that contains outpatient and inpatient diagnostic or treatment codes, vital status information and all prescribed medications. All claims can be linked in chronological order to provide a temporal sequence of all health services utilization.
Identification of sepsis patients and construction of the study cohort
Conforming to Sepsis-3, 28 we defined sepsis as a life-threatening organ dysfunction caused by a deregulated host response to an infection. The new sepsis definition is operationalized as International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes for the presence of either a bacterial or fungal infection plus one or more organ/system dysfunctions. We used the validated ICD-9-CM coding system developed by Angus and colleagues 3 with modification to identify infection and organ/system dysfunction (Supplementary Appendix S1).
We created a study cohort consisting of all emergency department (ED) or hospital treated patients with sepsis between 2001 and 2011. We defined index date as the first day of an ED or hospital visit as a result of sepsis. For patients with multiple hospitalization records of sepsis in a given yr, we used the first eligible hospitalization record as the index admission. Recurrent sepsis admissions were not considered in our analysis.
Medication exposure
We reviewed the literature for potential immunomodulatory medications affecting the outcome of sepsis and included them as covariates for adjustment (Supplementary Appendix S2). The use of specific medications was assessed by drug prescription record in a one-yr period before the index date. For example, yr 2000 was used for the assessment of specific medications in the 2001 identified sepsis patients. The standard outpatient practice in Taiwan is to dispense a prescription drug for three days, and assess whether to continue the drug in the follow up visit. Thus, a user with exposure to the medication of interest was defined by having a drug prescription record!seven days in the one yr before the indexed sepsis admission, unless stated otherwise. In this study, statin administration was defined as prescription of any of the following drugs: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin or simvastatin. 29 We have three types of statin users (chronic, current and past). The definition of primary exposure focused on the chronic use of statins, defined as the cumulative use of statins for more than 30 days in the one yr before the index sepsis admission. To analyse the effect of recency of statin use, we categorized exposure to statins into three mutually exclusive time windows as "current" when the supply of the most recent prescription lasted until index date or ended in the 90 days before the index date; "past," when it ended between 91 and 365 days before the index date; and "nonuse," when there was no recorded use in the yr before the index date. A prescription length of at least seven days is required to define current or past use. The reference category for all analyses consisted of non-use.
Editor's key points
• Studies of statin exposure in critically ill patients have reported mixed results.
• This study found that preadmission statin therapy was associated with a significant reduction in mortality in sepsis patients.
• But statins are unlikely to reverse the outcome of severely ill patients (e.g. requiring ventilator support).
Outcome and covariates
The primary outcome is 30-day all-cause mortality and the secondary outcome is 90-day all-cause mortality. Based on literature reports, we identified a total of 61 covariates (Supplementary Appendix S2) for adjustment in the following categories: patient characteristics, urbanization level, insurance premium level, pre-existing comorbidities, proxies for healthy lifestyle, health care facility utilization, and use of prescription medications. Four urbanization levels were determined according to standards published by the Institute of Occupational Safety & Health in Taiwan. 30 The standards include population density (persons per km 2 ), percentage of agricultural workers in the population, number of physicians per 100 000 persons in the population, and percentage of persons with college education or higher. Patient characteristic information was collected on index date, risk factor for sepsis was collected from 1999 to the index sepsis event, and health care utilization/use of specific medication was assessed one yr before the index sepsis event.
Data analysis
Baseline characteristics are presented as frequencies and percentages for categorical variables. Continuous variables were presented by mean standard deviation or median and interquartile range or, depending on the normality of variable distribution. To examine the differences in patient characteristics, we calculated absolute standardized difference. Standardized differences between statin users and non-users were calculated as the differences in the means or the percentage, divided by the pooled standard deviation.
The primary analysis investigated the risk of 30-day mortality in propensity score (PS)-matched cohort. PS was defined as the conditional probability of statin use derived from the logistic regression model, which included all potential predictors of statin prescription. Supplementary Appendix S2 lists the component variables of the PS model and their corresponding weights. Greedy matching algorithm (greedy five-to-one digit matching without replacement) was used to identify pairs composed of one sepsis patient without statin exposure and one sepsis patient who received statin with similar propensity score. We assessed the goodness of matching by the balance of each covariate (<10% standardized difference), using absolute standardized differences. After acceptable balance in measured baseline covariates has been achieved, all subsequent analyses were performed in the matched sample, using methods appropriate for the analysis of matched data in estimating the treatment effect and its statistical significance. 31 In all the analysis, we assessed the association between statin use and mortality by univariate COX-model stratified on the PS matched pairs. 32 Sensitivity analysis using robust variance estimator gave similar results (Supplementary Table S1 ), as it has been reported in previous simulation study. 31 Previous research suggests that users of statins are more likely to seek out preventive health services. To find out if our study design have sufficiently account for healthy user bias in the PS matched cohort, we compared the frequency of dental scaling between statin users and non-users, in the same statin assessment period. In Taiwan, all beneficiaries of NHI are eligible to receive free dental scaling every six months, and dental scaling is thus a good surrogate marker to examine healthy user bias.
Sensitivity analyses
We conducted sensitivity analyses using several alternative approaches to assess the robustness of our findings regarding the effect of statins on mortality. First, we performed multivariate-adjusted analysis by Cox regression model using the full sepsis cohort. We tested the proportional hazard assumption by introducing an interaction term of exposure and follow-up time in the model. In addition, the cumulative hazard function curve was examined for violation of the proportionality assumption in the Cox model. Second, we also tested the duration-response relationship by categorizing statin use into short term and long-term use, and estimated their relative effect adjusting for the PS. PS was entering into the Cox regression model as a continuous variable plus a quadratic term to allow nonlinearity. Lastly, we performed several subgroup analyses in patients with different existing comorbidities or acute organ dysfunctions. The consistency of treatment effects among subgroups was assessed by formal tests of interaction. We carried out all the analyses with SAS 9.4 for Windows (SAS Institute Inc, Cary, NC), and reported the data in accordance with STROBE guidelines. Figure 1 shows the cohort assembling process. In total, we identified 52 737 patients with sepsis between 2001 and 2011, of which 3559 (6.7%) were chronic statin users and 49 138 (93.3%) were non-users. Mean duration of chronic statin use was 134.52 (84.07) days and median duration was 114 (25-75 percentiles, 68-177) days. Table 1 summarizes the baseline characteristics of the study population. Compared with non-users, statin users were more affluent, had a higher burden of comorbidities, had higher number of psychiatric disorders, had a higher rate of health care utilization, and had a higher usage of specific medication.
Results
Cohort characteristics
Matching
To minimize baseline differences between statin users and nonusers, we carried out 1:1 PS matching on 61 variables. 3325 statin users were successfully matched to a non-user. After matching, the standardized differences in all the variables entered into the propensity score were less than 10%, indicating an adequate match (Table 1 and Supplementary Fig. S1 ).
Outcome
During hospitalization, statin users generally require more organ support and have a higher number of ICU admissions (36.3% vs 31.9%) when compared with non-users (Supplementary Table S2 ). Although statin users appeared to be more severely ill, the 30-day mortality rate in statin users (15.4% [555/3599]) was lower than the non-users (18.2% [8921/49 138]). We compared outcomes of the PS-matched cohort in Supplementary Table S3. In the PS matched cohort, the 30-day mortality rate in statin users was still significantly lower than the non-users (15.8% vs17.5%, P¼0.0048). To rule out the presence of healthy user bias, we compared the frequency of dental scaling during the statin exposure period. The frequency of dental scaling was comparable between statin users and non-users (16.5% vs 15.6%, P¼0.32). Table 2 shows the association between different types of statin use and the risk of 30-day mortality. In the primary PS-matched analysis, we found that use of statins was associated with significantly reduced mortality, when compared with non-user (HR, 0.88; 95% CI, 0.78-0.99). In the multivariate-adjusted Cox regression analysis, we found a comparable reduction in mortality (adjusted HR, 0.84; 95% CI, 0.77-0.91).
Main analyses
Next, we analysed whether the timing of statin use affects survival. We found users currently taking statins had lowered mortality (Supplementary Table S4 ). However, the former users who had discontinued these drugs did not derive any benefit in terms of sepsis mortality. We did not think differences in patient characteristics is the reason for the observed difference in mortality, as no significant differences in the baseline characteristics of chronic, current, and past users were observed (Supplementary Table S5 ).
In the analysis of secondary endpoints, we found that the protective effects of chronic use might extend to 90 days after sepsis admission. In general, use of statins was associated with a significantly lowered risk of mortality at 90 days in both the unadjusted and adjusted analysis (Supplementary Table S6 ). The only exception was in the PS matched analysis, where the differences were no longer significant (HR, 0.93, 95% CI: 0.83-1.04). This could be a reflection of the decreasing numbers of patients within this category. To investigate whether the hazard ratio changed over time, we created a cumulative hazard plots for 90-day mortality (Fig. 2) . In the cumulative hazard plots, we found that the protective effect of statin treatment was constant across the 90 days of observation ( Fig. 2A and B) .
Duration-response analysis
Our previous analysis suggested that use of statins was associated with a reduced mortality as compared with non-use. In Table 3 , we tried to gain insight into whether there was a duration-response relation between statin use and mortality. In the unadjusted analysis, longer-term use of statin (90-365 cumulative days) was observed to have a lower mortality rate (13.6% vs 15.7%) when compared with shorter-term use (7-90 cumulative days). However, statistical significance was not achieved after individual covariate adjustment (HR, 0.79, 0.59-1.06).
Subgroup analysis
To investigate whether there was a differential risk of 30-day mortality among different populations, we stratified patients with existing comorbidities or acute organ dysfunctions into different subgroups (Table 4 ). The effect of statin on mortality varies between different subgroups. The protective effect of statin vanished in patients requiring ventilator support or ICU admission (Interaction P<0.05). Compared with patients with one or two organ dysfunctions, ventilator support was also more frequently found in patients with more than three organ dysfunctions (95.4% vs 64.2%, Supplementary Table S7 ). The interaction term did not reach statistical significance for other subgroups.
Discussion
In this large population-based study including 52 737 patients with sepsis, we demonstrated that compared with patients that had never received statin treatment, chronic use of statins before the sepsis development was associated with an Continued approximately 12% reduction in mortality at 30 days. The beneficial effects of the use of statins were not affected by gender, presence of diabetes mellitus or heart failure, and tended to be more prominent in the less severely ill patients.
Previous studies on the beneficial effect of statin treatment on sepsis patients have been contradictory. Meta-analysis of 27 observational studies suggested that statins could improve the survival of sepsis by 7-93%. 13 However, a meta-analysis of five RCTs observed no improvement in in-hospital mortality (RR, 1.04; 95% CI, 0.87 -1.24), and a meta-analysis of three RCTs demonstrated no association with significant improvement in 28-day mortality (RR, 0.93; 95% CI, 0.46-1.89). 33 We hypothesize the difference in results between RCTs and observational studies might be partly explained by three factors: timing of statin treatment, severity of patient population, and size of the population. First, while the majority of observational studies investigated the use of statins before hospital admission, most of RCTs examined the de novo use of statin after hospital admission. The exceptional RCT conducted by Kruger and colleagues 16 discovered that prior statin use of at least two weeks duration was associated with a 23% lower 28-day mortality, while de novo statin therapy was not. Unfortunately the small sample size (n¼37) in Kruger and colleagues' trial limited the generalizability of their findings. There is biological and pharmacokinetic plausibility that the anti-inflammatory properties of statins require appropriate treatment duration before taking effect. A crossover double-blind trial by Plenge and colleagues 27 reported that at least a 14 days statin treatment is required to reduce the serum level of C-reactive protein. Chen and colleagues 34 also observed in a meta-analysis of eight RCTs an inverse relationship between the duration of pre-admission use of statins and the risk of post-operative atrial fibrillation. Our duration response analysis also suggested that statin users with >90 days duration of statin treatment have better survival than statin users with 7-90 days treatment duration. Second, the majority of RCTs were performed on ICU patients with severe sepsis or septic shock. 15 20 We think that statin alone cannot reverse the outcome of severely ill patients. As shown in our subgroup analysis, prior use of statin might not confer any beneficial effects in the more severe groups of patients (requiring ventilator support, or requiring ICU admission). A similar observation has also been noted for the effect of empirical antibiotic therapy on the outcome of bloodstream infections. Our group has previously discovered that the effect of appropriate empirical antibiotic therapy is more prominent in patients with a lower MEDS (mortality in Emergency Department Sepsis) scores, while patients with a higher MEDs scores do not show a substantial beneficial effect with appropriate antibiotic therapy. 35 Third, the sample size does matter in the analysis of RCTs or PS-matched observational studies, as large sample size allowed detection of subtle survival difference. A total of 1734 patient pairs, or 3468 patients are required for differentiating a 15% survival difference in a population with a background mortality rate of 25%, at a type 1 error rate of 5% and power of 80%. The required sample size would increase to 14 310 if the survival difference between statin users and nonusers was only around 10%. Most RCTs or PS matched observational studies did not have such a large sample size. 13 33 Our PS-matched sample included 6650 patients with a mortality rate of 23% in the control group, which has a sufficient power (90.9%) for detecting a 12% survival difference between statin users and nonusers. Given the rare incidence of sepsis in the general population (334-571/100 000), 607 355 to 1 038 328 general population may be needed for a prospective randomized trial, which is highly unlikely in the immediate future. 5 The ambiguity of the thus far published data means that more researches are required to determine the effectiveness, and mechanism of the prophylactic use of statins. There are several important limitations to this study. First, our study design does not permit direct mechanistic insights into how statins improve sepsis survival. However, we analysed the effect of statin on specific sepsis related organ dysfunctions (Supplementary Tables S3 and S7 ). We found that prior statin use could decrease the use of mechanical ventilation, but does not improve acute kidney injury requiring emergent hemodialysis and several cardiovascular complications. Our results agree with previous studies on pneumonia patients, which found that prior statin use could improve survival through decreasing pulmonary complications. Thomsen and colleagues 36 found that, when compared with non-users, statin users have 31% lower risk of pulmonary complications, and an improved survival by 31%. Mortensen and colleagues 37 also found that, the use of statins lowers risk of mechanical ventilation by 19% and improves survival by 26%. We think similar mechanisms can explain the observed survival improvement in our study. Second, we could not totally exclude the role of healthy user bias in the survival benefit of statin. Healthy-user bias describes the phenomenon in which patients prescribed with statins tend to have a higher socioeconomic status and health awareness and so are less likely to develop infections in general. 38 In our work, several countermeasures were taken to control for the possible healthy-user bias. First, statins in Taiwan are reimbursed without co-payment if a patient fulfilled pre-defined criteria for serum lipid levels. Second, we controlled socioeconomic status with a set of validated codes for geographical areas that are highly correlated with the degree of urbanization. 39 In addition, we controlled the insurance premium categories as a proxy for personal economic status. We also controlled for proxies for many lifestyle factors such as morbid obesity, or alcohol-related disorders. To assess whether we had sufficiently control for healthy user bias, we also compared the number of dental scaling for statin users and PS matched non-users. We found that there was no significant difference in the number of dental scaling for statin users and PS matched non-users. Third, this study also cannot totally exclude the possibility of surveillance bias, in which higher frequency of healthcare facility utilization in statin users might lead to a higher diagnostic rate and lower severity of sepsis. To minimize surveillance bias, we included annual frequency of hospitalization, outpatient visits, and emergency department visits into the PS model. The substantial baseline difference in frequency of health care service utilization between statin users and non-users was observed to be comparable after PS-matching.
Fourth, although we tried to be as comprehensive as possible in creating the PS score, the presence of unknown confounders cannot be ascertained. We must acknowledge that PS-matched analysis can only control for factors actually measured, and cannot control for unknown confounding variables like a randomized control trial. Finally, the PS-matched analysis cannot be generalized to the entire population. In creating the PSmatched cohort, we have sacrificed in some degree the external validity of our findings.
Conclusion
In conclusion, we found that preadmission use of statins might confer a small, but significant survival benefit when compared with patients who had never received any statins. This beneficial effect tended to be more prominent in less severe patients. Thus, patients who are at high risk of developing sepsis such as a history of sepsis, or immune-compromised conditions, may benefit from prophylactic use of statins if there are no contraindications. 
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